Results 21 to 30 of about 1,741 (166)

Tezepelumab in patients with allergic and eosinophilic asthma

Allergy, 2023
AbstractAsthma is a heterogeneous disease commonly driven by allergic and/or eosinophilic inflammation, both of which may be present in severe disease. Most approved biologics for severe asthma are indicated for specific phenotypes and target individual downstream type 2 components of the inflammatory cascade.
Marco Caminati, Roland Buhl, Jonathan Corren, Nicola A. Hanania, Harold Kim, Stephanie Korn, Marek Lommatzsch, Neil Martin, Andrea Matucci, Shuaib M. Nasser, Ian D. Pavord, Christian Domingo   +11 more
openaire   +4 more sources

SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma

Respiratory Research, 2020
Background Many patients with severe asthma continue to experience asthma symptoms and exacerbations despite standard-of-care treatment. A substantial proportion of these patients require long-term treatment with oral corticosteroids (OCS), often at high
Michael E. Wechsler, Gene Colice, Janet M. Griffiths, Gun Almqvist, Tor Skärby, Teresa Piechowiak, Primal Kaur, Karin Bowen, Åsa Hellqvist, May Mo, Esther Garcia Gil   +10 more
doaj   +1 more source

Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Patients with Moderate to Severe Asthma: The Phase 3b VECTOR Study

Pulmonary Therapy, 2023
Introduction Annual influenza vaccinations are recommended for adolescents and adults with moderate to severe asthma. This study investigated the effect of tezepelumab, a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin,
Jeremy Cole, Iwona Cąpała-Szczurko, Stephanie Roseti, Claudia Chen, Scott Caveney, Anastasia A. Aksyuk, Katie Streicher, Sandhia Ponnarambil, Gene Colice   +8 more
doaj   +1 more source

Tezepelumab treatment for allergic bronchopulmonary aspergillosis

Respirology Case Reports, 2023
AbstractAn 82‐year‐old man had been diagnosed with asthma. He experienced repeated exacerbations requiring treatment with a systemic corticosteroid despite being treated with medications including high‐dose fluticasone furoate/umeclidinium/vilanterol, montelukast sodium, and theophylline; treatment with mepolizumab was then initiated.
Hiroaki Ogata, Kachi Sha, Yasuaki Kotetsu, Aimi Enokizu‐Ogawa, Katsuyuki Katahira, Akiko Ishimatsu, Kazuhito Taguchi, Atsushi Moriwaki, Makoto Yoshida   +8 more
openaire   +3 more sources

CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma

Respiratory Research, 2020
Background Patients with severe, uncontrolled asthma, particularly those with a non-eosinophilic phenotype, have a great unmet need for new treatments that act on a broad range of inflammatory pathways in the airway.
Claire Emson, Sarah Diver, Latifa Chachi, Ayman Megally, Cherrie Small, John Downie, Jane R. Parnes, Karin Bowen, Gene Colice, Chris E. Brightling   +9 more
doaj   +1 more source

Safety and efficacy of tezepelumab vs. placebo in adult patients with severe uncontrolled asthma: a systematic review and meta-analysis

Scientific Reports, 2022
Patients with severe uncontrolled asthma still experience acute asthma symptoms and exacerbations, particularly those with non-eosinophilic inflammation who take the maximum amount of standard drug therapy.
Mahmoud Shaban Abdelgalil, Asmaa Ahmed Elrashedy, Ahmed K. Awad, Eman Reda Gad, Mahmoud M. Ali, Ramadan Abdelmoez Farahat, Bassant Hassan Shawki, Mohamed Abd-ElGawad   +7 more
doaj   +1 more source

Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma

Biomedicines, 2021
Alarmins are innate cytokines, including thymic stromal lymphopoietin (TSLP), interleukin-33 (IL-33), and interleukin-25 (IL-25), which are mainly produced by airway epithelium and exert a prominent role in asthma pathobiology.
Corrado Pelaia, Giulia Pelaia, Federico Longhini, Claudia Crimi, Cecilia Calabrese, Luca Gallelli, Angela Sciacqua, Alessandro Vatrella   +7 more
doaj   +1 more source

[Tezepelumab: a new option for the treatment of severe asthma]

Revista medica del Instituto Mexicano del Seguro Social, 2023
Resumen En Latinoamérica, el asma es un problema de salud pública con un impacto importante tanto para los pacientes como para los sistemas de salud. El mayor entendimiento de la fisiopatología y el reconocimiento del papel central que tiene la inflamación en la severidad del asma ha favorecido el desarrollo de anticuerpos monoclonales que tienen como ...
Maldonado-Ríos, Valente Armando, Ardila-Herrera, Juan Camilo, Galicia-Sánchez, Luz María, Celis-Preciado, Carlos Andrés   +3 more
openaire   +3 more sources

Tezepelumab in Adults with Uncontrolled Asthma

New England Journal of Medicine, 2017
In some patients with moderate-to-severe asthma, particularly those with noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the efficacy and safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody specific for the epithelial-cell-derived cytokine thymic stromal lymphopoietin (TSLP), in patients whose ...
Jonathan, Corren, Jane R, Parnes, Liangwei, Wang, May, Mo, Stephanie L, Roseti, Janet M, Griffiths, René, van der Merwe   +6 more
openaire   +2 more sources

Cost-effectiveness of tezepelumab in Canada for severe asthma

Journal of Medical Economics, 2023
To assess the cost-effectiveness of tezepelumab as add-on maintenance therapy compared with standard of care (SoC) for the treatment of patients with severe asthma in Canada. A cost utility analysis was conducted using a Markov cohort model with five health states (“controlled asthma”, “uncontrolled asthma”, “previously controlled asthma with ...
Mara Habash, Hannah Guiang, Irvin Mayers, Anna Quinton, Vivian Vuong, Aidan Dineen, Sumeet Singh, Danny Gibson, Adrian P. Turner   +8 more
openaire   +2 more sources